CISPLATIN INJECTION BP SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Nusipirk tai dabar

Prekės savybės Prekės savybės (SPC)
29-09-2020

Veiklioji medžiaga:

CISPLATIN

Prieinama:

SANDOZ CANADA INCORPORATED

ATC kodas:

L01XA01

INN (Tarptautinis Pavadinimas):

CISPLATIN

Dozė:

1MG

Vaisto forma:

SOLUTION

Sudėtis:

CISPLATIN 1MG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

10/50/100ML

Recepto tipas:

Prescription

Gydymo sritis:

ANTINEOPLASTIC AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0113245002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2022-07-25

Prekės savybės

                                PRODUCT MONOGRAPH
PR
CISPLATIN INJECTION BP
Sterile solution
1 MG/ML
(10mg, 50mg, 100mg cisplatin per vial)
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
Sandoz Canada Inc.
Date of Revision: September 29, 2020
110 Rue de Lauzon
Boucherville, QC
J4B 1E6
Submission Control No: 240523
________________________________________________________________________
_Cisplatin Injection BP_
_Page 2 of 21 _
PRODUCT MONOGRAPH
PR
CISPLATIN INJECTION BP
Sterile solution
1MG/ML
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
CAUTION
CISPLATIN INJECTION BP IS A POTENT DRUG AND SHOULD BE USED
ONLY BY PHYSICIANS EXPERIENCED WITH CANCER
CHEMOTHERAPEUTIC DRUGS (SEE WARNINGS AND PRECAUTIONS).
BLOOD COUNTS AS WELL AS RENAL AND HEPATIC FUNCTION TESTS
SHOULD BE TAKEN REGULARLY. DISCONTINUE THE DRUG IF
ABNORMAL DEPRESSION OF BONE MARROW OR ABNORMAL RENAL OR
HEPATIC FUNCTION IS SEEN.
ACTION AND CLINICAL PHARMACOLOGY
Cisplatin has biochemical properties similar to those of bifunctional
alkylating agents
producing inter-strand and intra-strand cross-links in DNA. It is
apparently not cell-cycle
specific.
PHARMACOKINETICS
Following bolus injection, or intravenous infusion over 2 to 7 hours,
of doses ranging
from 50 to 100 mg/m
2
, plasma cisplatin half-life is approximately 30 minutes. The ratios
of cisplatin to total, free (ultrafilterable) platinum in the plasma
range from 0.4 to 1.1
after a dose of 100 mg/m
2
.
Cisplatin does not undergo instantaneous and reversible binding to
plasma proteins
characteristic of normal drug-protein binding. However, the platinum
from cisplatin
becomes bound to plasma proteins. These complexes are slowly
eliminated with a half-
life of 5 days or more.
Following cisplatin doses of 20 to 120 mg/m
2
, the concentrations of platinum are highest
in liver, prostate and kidney, somewhat lower in bladder, muscle,
testicle, pancreas and
spleen and lowest in bowel, adrenal, heart, lung, cerebrum and
cerebellum. Platinum is
present in tissues for as long as 180 days after the last
administration. With the exception
____
                                
                                Perskaitykite visą dokumentą
                                
                            

Dokumentai kitomis kalbomis

Prekės savybės Prekės savybės prancūzų 29-09-2020

Ieškokite perspėjimų, susijusių su šiuo produktu